Clinical trials: Micropapillary Serous Carcinoma

Solid Tumors

Study of INCB123667 in Subjects With Advanced Solid Tumors

• Active, not recruiting
• Age: 18 years and older
• Phase 1

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with…

Trial name

NCT05238922

Testing

INCB0123667, Palbociclib, Bevacizumab

Where

41 sites in United States, France and 6 more

Volunteers

291 people

Sponsor

Incyte Corporation